GZ 389988
Alternative Names: GZ 389988A; GZ389988Latest Information Update: 05 Nov 2023
At a glance
- Originator Genzyme Corporation
- Developer Sanofi
- Class Antirheumatics; Small molecules
- Mechanism of Action TrkA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Osteoarthritis
Most Recent Events
- 31 Dec 2018 Discontinued - Phase-II for Osteoarthritis (In the elderly, In adults) in Germany (Intra-articular) before December 2018 (Sanofi pipeline, February 2019)
- 31 Dec 2018 Discontinued - Preclinical for Osteoarthritis in USA (Intra-articular) before December 2018 (Sanofi pipeline, February 2019)
- 31 Jul 2018 Sanofi announces its intention to submit regulatory application for Osteoarthritis in 2022